Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K ‑562 and colorectal HCT‑116 cancer cells
Int J Oncol. 2024 Apr;64(4):42. doi: 10.3892/ijo.2024.5630. Epub 2024 Mar 1.ABSTRACTTumor malignant cells are characterized by dysregulation of mitochondrial bioenergetics due to the 'Warburg effect'. In the present study, this metabolic imbalance was explored as a potential target for novel cancer chemotherapy. Imatinib (IM) downregulates the expression levels of SCΟ2 and FRATAXIN (FXN) genes involved in the heme‑dependent cytochrome c oxidase biosynthesis and assembly pathway in human erythroleukemic IM‑sensitive K‑562 chronic myeloid leukemia cells (K‑562). In the present study, it was investigated whether the ...
Source: International Journal of Oncology - March 1, 2024 Category: Cancer & Oncology Authors: Maria G Kakafika Areti A Lyta George I Gavriilidis Stefanos A Tsiftsoglou Androulla N Miliotou Ioannis S Pappas Ioannis S Vizirianakis Lefkothea C Papadopoulou Asterios S Tsiftsoglou Source Type: research
Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K ‑562 and colorectal HCT‑116 cancer cells
Int J Oncol. 2024 Apr;64(4):42. doi: 10.3892/ijo.2024.5630. Epub 2024 Mar 1.ABSTRACTTumor malignant cells are characterized by dysregulation of mitochondrial bioenergetics due to the 'Warburg effect'. In the present study, this metabolic imbalance was explored as a potential target for novel cancer chemotherapy. Imatinib (IM) downregulates the expression levels of SCΟ2 and FRATAXIN (FXN) genes involved in the heme‑dependent cytochrome c oxidase biosynthesis and assembly pathway in human erythroleukemic IM‑sensitive K‑562 chronic myeloid leukemia cells (K‑562). In the present study, it was investigated whether the ...
Source: International Journal of Oncology - March 1, 2024 Category: Cancer & Oncology Authors: Maria G Kakafika Areti A Lyta George I Gavriilidis Stefanos A Tsiftsoglou Androulla N Miliotou Ioannis S Pappas Ioannis S Vizirianakis Lefkothea C Papadopoulou Asterios S Tsiftsoglou Source Type: research
Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K ‑562 and colorectal HCT‑116 cancer cells
Int J Oncol. 2024 Apr;64(4):42. doi: 10.3892/ijo.2024.5630. Epub 2024 Mar 1.ABSTRACTTumor malignant cells are characterized by dysregulation of mitochondrial bioenergetics due to the 'Warburg effect'. In the present study, this metabolic imbalance was explored as a potential target for novel cancer chemotherapy. Imatinib (IM) downregulates the expression levels of SCΟ2 and FRATAXIN (FXN) genes involved in the heme‑dependent cytochrome c oxidase biosynthesis and assembly pathway in human erythroleukemic IM‑sensitive K‑562 chronic myeloid leukemia cells (K‑562). In the present study, it was investigated whether the ...
Source: International Journal of Oncology - March 1, 2024 Category: Cancer & Oncology Authors: Maria G Kakafika Areti A Lyta George I Gavriilidis Stefanos A Tsiftsoglou Androulla N Miliotou Ioannis S Pappas Ioannis S Vizirianakis Lefkothea C Papadopoulou Asterios S Tsiftsoglou Source Type: research
Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K ‑562 and colorectal HCT‑116 cancer cells
Int J Oncol. 2024 Apr;64(4):42. doi: 10.3892/ijo.2024.5630. Epub 2024 Mar 1.ABSTRACTTumor malignant cells are characterized by dysregulation of mitochondrial bioenergetics due to the 'Warburg effect'. In the present study, this metabolic imbalance was explored as a potential target for novel cancer chemotherapy. Imatinib (IM) downregulates the expression levels of SCΟ2 and FRATAXIN (FXN) genes involved in the heme‑dependent cytochrome c oxidase biosynthesis and assembly pathway in human erythroleukemic IM‑sensitive K‑562 chronic myeloid leukemia cells (K‑562). In the present study, it was investigated whether the ...
Source: International Journal of Oncology - March 1, 2024 Category: Cancer & Oncology Authors: Maria G Kakafika Areti A Lyta George I Gavriilidis Stefanos A Tsiftsoglou Androulla N Miliotou Ioannis S Pappas Ioannis S Vizirianakis Lefkothea C Papadopoulou Asterios S Tsiftsoglou Source Type: research
Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K ‑562 and colorectal HCT‑116 cancer cells
Int J Oncol. 2024 Apr;64(4):42. doi: 10.3892/ijo.2024.5630. Epub 2024 Mar 1.ABSTRACTTumor malignant cells are characterized by dysregulation of mitochondrial bioenergetics due to the 'Warburg effect'. In the present study, this metabolic imbalance was explored as a potential target for novel cancer chemotherapy. Imatinib (IM) downregulates the expression levels of SCΟ2 and FRATAXIN (FXN) genes involved in the heme‑dependent cytochrome c oxidase biosynthesis and assembly pathway in human erythroleukemic IM‑sensitive K‑562 chronic myeloid leukemia cells (K‑562). In the present study, it was investigated whether the ...
Source: International Journal of Oncology - March 1, 2024 Category: Cancer & Oncology Authors: Maria G Kakafika Areti A Lyta George I Gavriilidis Stefanos A Tsiftsoglou Androulla N Miliotou Ioannis S Pappas Ioannis S Vizirianakis Lefkothea C Papadopoulou Asterios S Tsiftsoglou Source Type: research
GSE221906 Concomitant inhibition of the thioredoxin system and non-homologous DNA repair potently sensitizes Philadelphia-positive lymphoid leukemia to tyrosine kinase inhibitors
Contributors : Lukasz Komorowski ; Joanna Madzio ; Agata Pastorczak ; Kacper Szczygie ł ; Martyna Poprzeczko ; Klaudyna Fidyt ; Maksymilian Bielecki ; Jaromir Hunia ; Agnieszka Dabkowska ; Tomasz Stoklosa ; Magdalena Winiarska ; Elzbieta Patkowska ; Jakub Golab ; Malgorzata FirczukSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBCR-ABL1 gene fusion is an essential driver lesion in both chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL). While tyrosine kinase inhibitors (TKIs) cure up to 95% of CML patients, 50 % of...
Source: GEO: Gene Expression Omnibus - March 1, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
GSE198142 Targeting PABPC1 suppresses chronic myeloid leukemia disease progression by controlling BCR-ABL1 translation
Contributors : Chenguang Sun ; Zhongyang Chen ; Yanni Ma ; Jia YuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensPABPC1 mediated protein synthesis control might be important for chronic myeloid leukemia (CML) disease progression. Here, we use the PABPC1 enhanced cross-linking and immunoprecipitation sequencing (eCLIP-seq) to capture PABPC1 directly bound RNAs as well as the ribosome profiling (Ribo-seq) to examine the ribosome protected mRNA fragments in control and PABPC1 silenced K562 cells. We integrated the eCLIP-seq and Ribo-seq data and found that 1496 out of the 6840 PABPC...
Source: GEO: Gene Expression Omnibus - March 1, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Renin-Angiotensin System Inhibitors Suppress the Growth of Leukemia Cells
CONCLUSION: RAS inhibitors can be repurposed as molecular-targeted drugs for leukemia. However, the concentrations of the inhibitors were much higher than those in the plasma of patients with hypertension. Therefore, further investigation is required for their clinical use.PMID:38423665 | DOI:10.21873/anticanres.16913 (Source: Cell Research)
Source: Cell Research - February 29, 2024 Category: Cytology Authors: Mai Itoh Shun Sasaki Shuji Tohda Source Type: research
Using Proton Pump Inhibitors is not Associated with Adverse Outcomes in Patients with Chronic Myeloid Leukemia Treated with Dasatinib
Treatment with the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has markedly improved the outcome of patients with chronic myeloid leukemia (CML). These oral therapies are convenient but raise the concern of potential gastrointestinal malabsorption due to drug-drug interactions. This could compromise the treatment efficacy and result in adverse events (e.g., increasing the concentration of a drug beyond the therapeutic index).1 An important factor influencing TKI absorption is the change in gastric pH. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 29, 2024 Category: Hematology Authors: Fadi G. Haddad, Cedric Nasnas, Koji Sasaki, Shilpa Paul, Ghayas C. Issa, Caitlin Rausch, Elias Jabbour, Hagop Kantarjian Source Type: research
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
Leukemia, Published online: 29 February 2024; doi:10.1038/s41375-024-02187-wLong-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance (Source: Leukemia)
Source: Leukemia - February 29, 2024 Category: Hematology Authors: Simone Claudiani Farhan Chughtai Afzal Khan Chloe Hayden Fiona Fernando Jamshid Khorashad Victoria Orovboni Glenda Scandura Andrew Innes Jane F. Apperley Dragana Milojkovic Source Type: research
Targeted disruption of the < em > BCR-ABL < /em > fusion gene by Cas9/dual-sgRNA inhibits proliferation and induces apoptosis in chronic myeloid leukemia cells
This study aims to explore the efficiency of novel CRISPR-associated protein 9 (Cas9)/dual-single guide RNA (sgRNA)-mediated disruption of the BCR-ABL fusion gene by targeting BCR and c-ABL introns. A co-expression vector for Cas9 green fluorescent protein (GFP)/dual-BA-sgRNA targeting BCR and c-ABL introns is constructed to produce lentivirus to affect BCR-ABL expression in CML cells. The effects of dual-sgRNA virus-mediated disruption of BCR-ABL are analyzed via the use of a genomic sequence and at the protein expression level. Cell proliferation, cell clonogenic ability, and cell apoptosis are assessed after dual sgRNA ...
Source: Acta Biochimica et Biophysica Sinica - February 28, 2024 Category: Biochemistry Authors: Jianling Zeng Xinquan Liang Lili Duan Fenghua Tan Liujie Chen Jiayao Qu Jia Li Kai Li Dixian Luo Zheng Hu Source Type: research
Targeted disruption of the < em > BCR-ABL < /em > fusion gene by Cas9/dual-sgRNA inhibits proliferation and induces apoptosis in chronic myeloid leukemia cells
This study aims to explore the efficiency of novel CRISPR-associated protein 9 (Cas9)/dual-single guide RNA (sgRNA)-mediated disruption of the BCR-ABL fusion gene by targeting BCR and c-ABL introns. A co-expression vector for Cas9 green fluorescent protein (GFP)/dual-BA-sgRNA targeting BCR and c-ABL introns is constructed to produce lentivirus to affect BCR-ABL expression in CML cells. The effects of dual-sgRNA virus-mediated disruption of BCR-ABL are analyzed via the use of a genomic sequence and at the protein expression level. Cell proliferation, cell clonogenic ability, and cell apoptosis are assessed after dual sgRNA ...
Source: Acta Biochimica et Biophysica Sinica - February 28, 2024 Category: Biochemistry Authors: Jianling Zeng Xinquan Liang Lili Duan Fenghua Tan Liujie Chen Jiayao Qu Jia Li Kai Li Dixian Luo Zheng Hu Source Type: research
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial
Leukemia, Published online: 28 February 2024; doi:10.1038/s41375-024-02184-zCorrection: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial (Source: Leukemia)
Source: Leukemia - February 28, 2024 Category: Hematology Authors: Hjalmar Flygt Stina S öderlund Johan Richter Susanne Saussele Perttu Koskenvesa Leif Stenke Satu Mustjoki Andreja Dimitrijevic Jesper Stentoft Waleed Majeed Lydia Roy Dominik Wolf Arta Dreimane Bj ørn Tore Gjertsen Tobias Gedde-Dahl Erik Ahlstrand Berit Source Type: research
Genetically predicted telomere length and the risk of 11 hematological diseases: a Mendelian randomization study
CONCLUSIONS: The MR analysis revealed a positive association between genetically predicted longer TL and an increased risk of developing ALL, AML, CLL, MANTLE, and HODGKIN. This study further supports the notion that cells with longer TL have greater proliferative and mutational potential, leading to an increased risk of certain HDs.PMID:38393686 | DOI:10.18632/aging.205583 (Source: Aging)
Source: Aging - February 23, 2024 Category: Biomedical Science Authors: Yimin Wang Qi Liu Shibing Liang Minghao Yao Huimin Zheng Dongqing Hu Yifei Wang Source Type: research
Identification and clinical implications of recurrent PAX5::MLLT3 fusion in lymphoid blastic phase chronic myeloid leukemia
Int J Lab Hematol. 2024 Feb 23. doi: 10.1111/ijlh.14245. Online ahead of print.NO ABSTRACTPMID:38389449 | DOI:10.1111/ijlh.14245 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - February 23, 2024 Category: Hematology Authors: Lijun Wang Yu Chen Qingyuan Wang Meng Xiang Zhao Zeng Zhibo Zhang Fenghong Zhang Suning Chen Mengxing Xue Source Type: research
